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Supplementary data 
Systematic review and distinct trial designs 
A systematic review was carried out to identify relevant data. Searches were carried out in Medline 
and Medline in process (Ovid SP, from 1948 to present), Embase (Ovid SP, from 1988 to present) and 
the Cochrane Central Register of Controlled Trials (CENTRAL) and were run from 1990 to 27
th
 June 
2011 (28
th
 June for CENTRAL). Abstracts were screened by two reviewers. Reference lists of 
included trials were also reviewed. Search strategies and the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) diagram are provided at the end of this document.  
Twenty-two trials were included in the review. Characteristics of the trials are provided as Table S1, 
along with references to the associated publications. These data were extracted from the trial 
publications identified by the systematic review. Missing data may therefore reflect incomplete 
reporting rather than the actual data collected. Missing data for the individual patient database is 
recorded in Table 1 of the main text. 
There is variation in patient characteristics across trials with respect to age, gender, New York Heart 
Association (NYHA) class, QRS duration, left bundle branch block (LBBB) morphology and the 
proportion of patients with disease of ischaemic aetiology. Less difference was seen with respect to 
mean left ventricular ejection fraction (LVEF) (21-27% across all trials). These differences in average 
patient characteristics reflect differences in the trial inclusion criteria.  However, the differences in 
average characteristics should not obscure the real similarities across subgroups of the trials. For 
example, four of the five largest trials (Companion, Multicenter Automatic Defibrillator Implantation 
Trial II (MADIT II), Resynchronisation-defibrillation for Ambulatory heart Failure Trial (RAFT), and 
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)) all contained some proportion of patients 
with NYHA III, QRS duration≥120ms and LVEF≤30%. Study quality was assessed using the risk of 
bias assessment tool recommended by the National Institute for Health and Care Excellence[1], and is 
summarised in Table S2.  
Of the eight studies not included in the individual patient data set, two were not sponsored by the 
manufacturers (Cat and Piccirillo et al.); two were not available (Amiovirt, Pinter et al.); two data sets 
could not be reconciled with the published data and were therefore not considered of sufficient quality 
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for inclusion in the analysis (MUltisite STImulation in Cardiomyopathies (MUSTIC); 
Resynchronisation for HemodYnamic Treatment for Health failure Management ICD (RHYTHM-
ICD)) and two were not identified by the systematic review until data requests had been sent out and 
the analysis had started (Vector; Respond). 
The dataset holder for MUSTIC (Medtronic) was unable to reconcile the available datasets (which 
were locked over 10 years ago) with the data in the public domain. These data were therefore not 
supplied to the authors for analysis. The data for RHYTHM-ICD were released to the authors 
however the authors in collaboration with the data holder (St. Jude Medical) were unable to reconcile 
the number of deaths between the FDA report for this study (9 deaths for CRT-D and 3 for ICD) with 
the individual patient data sets (which showed 7 and 2 deaths respectively). Given these concerns 
regarding the individual patient data this data was not included in the adjusted analysis. The 
unadjusted analysis was however run with and without data from the studies for which individual 
patient data were unavailable in order to assess the potential for omission of these studies to influence 
the study results.  
Contak-CD and REsynchonization reVErses Remodeling in Systolic left vEntricular dysfunction 
(REVERSE) were not straightforward parallel-group designs comparing the devices of interest. 
Patient allocation in REVERSE was to either CRT-D or CRT-P implantation based on clinical 
guidelines or physician judgement. Patients were then randomised to resynchronisation therapy “on” 
or “off”. In addition, patients were programmed to have CRT switched “on” after 12 months in the US 
and 24 months in Europe. REVERSE is, therefore, considered as four trials: US and European trials in 
CRT-D implanted patients comparing CRT-D to ICD (representing the majority of patients); and US 
and European trials in CRT-P implanted patients comparing CRT-P to medical therapy.  
Contak-CD initially randomised patients to CRT-P or medical therapy with cross-over to the other 
therapy after 3 months. Part way through the trial, patients enrolled into a six-month parallel group 
trial. These designs can, therefore, be considered as two separate trials (Contak-CD Ph1 (up to 3 
months) and Contak-CD Ph2, respectively).  
The SCD-HeFT trial randomised patients to three arms: conventional therapy plus placebo; 
conventional therapy plus amiodarone and conventional therapy plus ICD. As the focus of this 
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analysis was to compare device therapies this posed the question of whether one or both of the non-
device arms should be included in the analysis. Based on clinical advice and the all-cause mortality 
endpoint results from this study (amiodarone vs. placebo hazard ratio 1.06 (95% CI 0.86-1.30)), the 
amiodarone and placebo arms of this trial were pooled in the analysis.  
Miracle ICD and Miracle ICD II, although reported in separate publications, actually describe a single 
trial so this is considered as a single trial in the analysis.  
Data from publications were extracted by one reviewer and checked by another. Individual patient 
data were requested in a standardised format from the three device manufacturers. A wide range of 
patient characteristic, study characteristic and outcome data were extracted from the trials. However, 
the focus of the network meta-analysis is the all-cause mortality outcome.  
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Statistical methods 
Methods for combining binary and hazard ratio data 
Binary data were included using a binomial likelihood for the cumulative probability of death in arm k 
of study s (Fs,k). From this, the log-cumulative hazard ln(Hs,k) is derived using a complementary log-
log link transformation [2] . The log-cumulative hazard is estimated as the sum of a study-specific 
‘baseline’ term 𝛼𝑠 and a treatment effect coefficient 𝛽𝑘  where 𝛽1 = 0 and 𝛽𝑏 represents the treatment 
effect for the baseline treatment in study s. 
ln(𝐻𝑠,𝑘) = 𝛼𝑠 + 𝛽𝑘 − 𝛽𝑏 
Equation 1 
Hazard ratio data were incorporated into the NMA model using a normal likelihood for the log-hazard 
ratio ln (𝐻𝑅𝑠,𝑘,𝑏) for study s comparing treatment k to treatment b. These were estimated from each 
study using a cox proportional hazards model. The log-hazard ratio estimates are then included in a 
treatment effect model to allow the hazard ratio data to also inform the 𝛽𝑘 : 
ln(𝐻𝑅𝑠,𝑘,𝑏) = 𝛽𝑘 − 𝛽𝑏 
Equation 2 
Equations 1 and 2 are replaced by equations 3 and 4 for the random effects model where 𝑟𝑒𝑠,𝑘 is the 
random effect deviation for arm k of study s and is assumed to be normally distributed with zero mean 
and variance σ2/2, where σ2 is the random effect variance for a treatment comparison.  
ln(𝐻𝑠,𝑘) = 𝛼𝑠 + 𝛽𝑘 − 𝛽𝑏 + 𝑟𝑒𝑠,𝑘 − 𝑟𝑒𝑠.𝑏 
Equation 3 
ln(𝐻𝑅𝑠,𝑘,𝑏) = 𝛽𝑘 − 𝛽𝑏 + 𝑟𝑒𝑠,𝑘 − 𝑟𝑒𝑠.𝑏 
Equation 4 
 
For ease of implementation this model was implemented in Winbugs and is a Bayesian analysis. 
Vague priors were used in this analysis. Two sets of initial values were used and convergence was 
assessed by examining caterpillar plots and Brooks Gelman-Rubin (BGR) statistics [3]. Fixed and 
random effects models were fitted and the deviance information criteria (DIC) was used to compare 
5 
 
their fit [4].  Autocorrelation was also examined. Fixed effects models were preferred according to the 
deviation information criterion (DIC) in the unadjusted analysis and are presented in the main text.  
 
Methods for adjusted analysis 
The unadjusted model takes the following form:   
𝜆𝑖𝑠 = 𝜆𝑠(𝑡) ∙ exp (𝛽𝐶𝑅𝑇−𝑃𝐷𝐶𝑅𝑇−𝑃 𝑖𝑠 + 𝛽𝐶𝑅𝑇−𝐷𝐷𝐶𝑅𝑇−𝐷 𝑖𝑠 + 𝛽𝐼𝐶𝐷𝐷𝐼𝐶𝐷 𝑖𝑠) 
Equation 5 
Where λis is the hazard for patient i in study s, λs(𝑡) is the baseline hazard function in study s which 
will vary over time t, the β’s are the treatment coefficients expressing the efficacy of the devices vs. 
medical therapy and the 𝐷𝐷𝐸𝑉𝑖𝑠 are device dummy variables which take the value 1 if patient i in 
study s was randomised to that device and 0 otherwise. This model is equivalent to Equation 2 where 
the hazard ratio data from each trial is synthesised.  
When device-by-baseline characteristic interaction effects are included the model expands to take the 
following form:  
𝜆𝑖𝑠 = 𝜆𝑠(𝑡) ∙ exp (𝛽𝑋𝑋𝑖𝑠 + 𝛽𝐶𝑅𝑇−𝑃𝐷𝐶𝑅𝑇−𝑃 𝑖𝑠 + 𝛽𝐶𝑅𝑇−𝐷𝐷𝐶𝑅𝑇−𝐷 𝑖𝑠 + 𝛽𝐼𝐶𝐷𝐷𝐼𝐶𝐷 𝑖𝑠
+ 𝛽𝑋.𝐶𝑅𝑇−𝑃𝐷𝐶𝑅𝑇−𝑃 𝑖𝑠𝑋𝑖𝑠 + 𝛽𝑋.𝐶𝑅𝑇−𝐷𝐷𝐶𝑅𝑇−𝐷 𝑖𝑠𝑋𝑖𝑠 + 𝛽𝑋.𝐼𝐶𝐷𝐷𝐼𝐶𝐷 𝑖𝑠𝑋𝑖𝑠) 
Equation 6 
Where 𝑋𝑖𝑠 and 𝛽𝑋 are the baseline variable (or vector of covariables) and coefficient on the baseline 
variable respectively and 𝛽𝑋.𝐷𝐸𝑉 is the coefficient on the device by baseline variable interaction. The 
𝛽𝑋 are nuisance parameters in this model. This model was fitted using the coxph function in the R 
package survival.  
Continuous variables were dichotomised to facilitate presentation. A quadratic model was fitted which 
showed that the efficacy of CRT-P and CRT-D increases broadly linearly between QRS durations of 
120ms and 150ms and then levels off after 150ms. This suggests that these categories are reasonable, 
though they may not fully reflect heterogeneity in response between QRS duration of 120 and 150ms. 
For age, efficacy of ICD increases and efficacy of CRT-P decreases with age, until a plateau is 
observed after approximately 60 years. For simplicity, age was therefore converted to a two level 
variable of <60 and ≥60 years. Again this may miss some of the heterogeneity in response to therapy 
in the <60 category. 
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Multiple imputation methods 
The exploratory analyses used a complete case approach; prior-MI was used as a proxy for ischaemic 
aetiology when data on ischaemic aetiology was missing. For the final adjusted model, multiple 
imputation was used to address missing baseline variables. Imputation was carried out in the Amelia 
package
1
. Five imputed data sets were created. The approach used assumes that the complete 
(unobserved) data set has a multivariate normal distribution and that data are missing at random. 
Draws from the estimated complete data multivariate normal distribution are made using a 
combination of an expectation-maximisation algorithm and bootstrapping.  
 
Individual study results 
Individual study results for studies included in the individual patient dataset are shown in Figure S1. 
Q tests were conducted to assess the significance of any heterogeneity in the trials and the I
2
 statistic 
was calculated to quantify the degree of heterogeneity.[5] Multiple studies were reported for three of 
the pairwise comparisons (see Figure S1). The p-values for the Q test were 0.56, 0.10 and 0.48 for 
CRT-P vs. OMT, ICD vs. OMT and CRT-D vs. ICD respectively. The I
2
 statistics for the same 
comparisons were 0%, 52% and 0% respectively. There is therefore moderate evidence of 
heterogeneity within the ICD vs. OMT comparison.  
 
Final model 
All coefficients for the final model are presented as Table S3.  
Proportional hazards tests were run for all main effects and interaction effects. The Schoenfeld 
residual-based test suggested by Grambsch and Therneau was used.[6] Tests of the proportional 
hazards assumption did not suggest that this was violated (global p-value = 0.684), nor did plots of the 
Schoenfeld residuals suggest time trends.   
                                                          
1
 http://cran.r-project.org/web/packages/Amelia/vignettes/amelia.pdf  
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Sensitivity analysis 
The patients included in the current analysis are highly heterogeneous and this heterogeneity is 
expected to result in differences in treatment effects. The adjusted analysis presented aims to reflect 
this heterogeneity via the inclusion of interactions between the device effects and a series of 
covariables. These covariables are assumed to have multiplicative and independent impacts on the 
hazard ratio of each device, however it is possible (and likely) that these relationships do not perfectly 
hold. A sensitivity analysis was therefore run restricting the main analysis to those patients with 
QRS≥120ms and with NYHA II-IV as this group were expected to be more homogeneous with 
respect to treatment effects. The results are presented as Table S4 and Table S5. The results are very 
similar with the exception of the main effects of CRT-D, CRT-P and age and the interaction of age 
with CRT-D and CRT-P effectiveness (Table S4) which are somewhat different although confidence 
intervals from the two analyses are overlapping. The net impact of these changes to the model 
coefficients for predictions in specific patient groups is shown in Table S5. This shows that 
predictions in the majority of patients remain similar with the exception of patients with age <60 
years. The sensitivity analysis suggests that these patients experience higher effects of CRT-P and 
CRT-D. The sensitivity analysis is associated with increased uncertainty as shown by generally wider 
confidence intervals in Table S3 and S4, this reflects the smaller number of patients analysed. 
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Supplemental Tables 
Table S1. Baseline characteristics of studies included in systematic review 
Study Arm  N * 
Age- mean 
(SD) 
Male- 
n (%) 
NYHA I n (%) 
Mean 
LVEF 
(SD) 
QRS 
duration 
(ms)- Mean 
(SD)  
LBBB 
morphology 
-n (%) 
Ischaemic 
-n(%) I II III IV 
AMIOVIRT 
[7 8] 
ICD 
103 
58 (11) 
34 
(67) 
10 (18) 33 (64) 8 (16) 0 22 (10) NR 21 (42) 0 
MT 60 (12) 
38 
(74) 
7(13) 33 (63) 12 (24) 0 23 (8) NR 28 (53) 0 
CARE-HF [9-
13] 
CRT
-P 
813 
67 (60-73)† 
304 
(74) 
0 0 386 (94) 23 (6) 
25 (21-
29)† 
160 (152-
180)† 
NR 165 (40) 
MT 66 (59-72)† 
293 
(73) 
0 0 377 (93) 27 (7) 
25 (22-
29)† 
160 (152-180) 
† 
NR 144 (36) 
CAT [14-16] 
ICD 
104 
52 (12) 
43 
(86) 
0 33 (66.7) 17 (33.3) 0 24 (6) 102 (29) 42 (84.6) NR 
MT 52 (10) 40 0 35 (64.1) 19 (35.8) 0 25 (8) 114 (29) 44 (81.8) NR 
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Study Arm  N * 
Age- mean 
(SD) 
Male- 
n (%) 
NYHA I n (%) 
Mean 
LVEF 
(SD) 
QRS 
duration 
(ms)- Mean 
(SD)  
LBBB 
morphology 
-n (%) 
Ischaemic 
-n(%) I II III IV 
(74) 
COMPANIO
N [17-20] 
CRT
-P 
152
0 
67 
413 
(67) 
0 0 537 (87) 80 (13) 20.2 160
2
 426 (69) 333 (54) 
CRT
-D 
66 
399 
(67) 
0 0 512 (86) 83 (14) 22.2 160
2
 434 (73) 327 (55) 
MT 68 
213 
(69) 
0 0 253 (82) 55 (18) 22.2 158† 216 (70) 182 (59) 
Contak-CD 
[21 22]  
CRT
-D 
490 
66 (11) 
208 
(85) 
0 78 (32) 147 (60) 20(8) 21 (7) 160(27) 132 (54) 164 (67) 
ICD 66 (11) 
203 
(83) 
0 81 (33) 140 (57) 25 (10) 22 (7) 156(26) 135 (55) 174 (71) 
DEFINITE 
[23 24] 
ICD 458 
58.4 (20.3-
83.9) ‡ 
166 
(72.5) 
58 (25.3) 124 (54.2) 47 (20.5) 0 
20.9 (7 - 
35) ‡ 
114.7 ( 78 - 
196) ‡ 
45 (19.7) 0 
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Study Arm  N * 
Age- mean 
(SD) 
Male- 
n (%) 
NYHA I n (%) 
Mean 
LVEF 
(SD) 
QRS 
duration 
(ms)- Mean 
(SD)  
LBBB 
morphology 
-n (%) 
Ischaemic 
-n(%) I II III IV 
MT 
58.1 (21.8-
78.7) ‡ 
160 
(69.9) 
41 (17.9) 139 (60.7) 49 (21.4) 0 
21.8 (10 
- 35) ‡ 
115.5 (79 -
192) ‡ 
45 (19.7) 0 
MADIT [25 
26] 
ICD 
196 
62 (9) 
92 
(97) 
35 (37) 60 (63) 0 27 (7) NR 7 (7) 95 (100) 
MT 64 (9) 
92 
(91) 
33 (33) 68 (67) 0 25 (7) NR 8 (8) 101 (100) 
MADIT II [27 
28] 
ICD 
123
2 
64 (10) 
623 
(84) 
260 (35) 260 (35) 186 (25) 37 (5) 23 (5) NR 141 (19) 742 (100) 
MT 65 (10) 
417 
(85) 
191 (39) 167 (34) 113 (23) 20 (4) 23 (6) NR 88 (18) 490 (100) 
MADIT-CRT 
[29-31] 
CRT
-D 
182
0 
65 (11) 
814 
(74.7) 
152 (14.0) 937 (86.0) 0 0 24 (5) NR 761 (69.9) 598 (55) 
ICD 64 (11) 553 113 (15.5) 618 (84.5) 0 0 24 (5) NR 520 (71.3) 401 (55) 
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Study Arm  N * 
Age- mean 
(SD) 
Male- 
n (%) 
NYHA I n (%) 
Mean 
LVEF 
(SD) 
QRS 
duration 
(ms)- Mean 
(SD)  
LBBB 
morphology 
-n (%) 
Ischaemic 
-n(%) I II III IV 
(75.6) 
MIRACLE 
[32-34] 
CRT
-P 
453 
63.9 (10.7) 
155 
(68) 
0 0 205 (90) 23 (10) 
21.8 
(6.3) 
167 (21) NR 114 (50) 
MT 64.7 (11.2) 
153 
(68) 
0 0 205 (91) 20 (9) 
21.6 
(6.2) 
165 (20) NR 131 (58) 
MIRACLE-
ICD [35] 
CRT
-D 
369 
66.6 (11.3) 
142 
(75.9) 
0 0 
165 
(88.2) 
22 (11.8) 
24.2 
(6.5) 
165 (22) NR 119 (64) 
ICD 67.6 (9.2) 
141 
(77.5) 
0 0 
163 
(89.6) 
19 (10.4) 
23.9 
(6.0) 
162 (22) NR 138 (75.8) 
MIRACLE-
ICD II [36] 
CRT
-D 
186 
63.0 (12.8) 
75 
(88.2) 
0 85 (100) 0 0 
24.4 
(6.6) 
166 (25) NR 47 (55.3) 
ICD 63.1 (12.1) 
91 
(90.1) 
0 101 (100) 0 0 
24.6 
(6.7) 
165 (23) NR 59 (58.4) 
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Study Arm  N * 
Age- mean 
(SD) 
Male- 
n (%) 
NYHA I n (%) 
Mean 
LVEF 
(SD) 
QRS 
duration 
(ms)- Mean 
(SD)  
LBBB 
morphology 
-n (%) 
Ischaemic 
-n(%) I II III IV 
MUSTIC [37] 
CRT
-Pǁ 
58 
64 (11) 
19 
(66) 
0 0 29 (100) 0 
23 (7) § 
172 (22) 
58 (87%) 25 (37%) 
MTǁ 
 
64 (8) 
24 
(83) 
0 0 29 (100) 0 175 (19) 
Piccirillo et al 
[38] 
ICD 
31 
65 (8) 
12 
(80) 
0 0 5 (33) 10 (67) 22 (8) 159 (8) NR 15 (100) 
CRT
-D 
65 (4) 
13 
(81) 
0 0 5 (31) 11 (69) 23 (4) 160 (4) NR 16 (100) 
Pinter et al 
[39] 
CRT
-D 
72 
66.3 (8.6) 
28 
(77.8) 
NR NR NR NR 
21.2 
(7.9) 
NR NR NR 
ICD 66.1 (8.8) 
29 
(80.6) 
NR NR NR NR 24 (8.3) NR NR NR 
RAFT [40 41] CRT 179 66.1 (9.3) 758 0 708 (79.2) 186 0 22.6 157 (23.6) 652 (72.9) 614 (68.7) 
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Study Arm  N * 
Age- mean 
(SD) 
Male- 
n (%) 
NYHA I n (%) 
Mean 
LVEF 
(SD) 
QRS 
duration 
(ms)- Mean 
(SD)  
LBBB 
morphology 
-n (%) 
Ischaemic 
-n(%) I II III IV 
-D 8 (84.8) (20.8) (5.4) 
ICD 66.2 (9.4) 
732 
(81.0) 
0 730 (80.8) 
174 
(19.2) 
0 
22.6 
(5.1) 
158.3 (24) 643 (71.1) 587 (64.9) 
RESPOND 
[42] 
CRT
-P 
60 
66.7 (7.86) 
25 
(86.2) 
0 0 19 (65.5) 10 (34.5) 
22.3 
(8.42) 
91.5 (10.6) NR 22 (75.9) 
MT 69.3 (10.2) 
24 
(77.4) 
0 0 26 (83.9) 5 (16.1) 
22.1 
(10.2) 
97.8 (12.9) NR 28 (90.3) 
RETHINQ 
[43 44] 
CRT
-D 
172 
60 (12) 
62 
(12) 
0 0 87 (100) 0 25 (5) 107 (12) NR 47 (54) 
ICD 58 (14) 
49 
(58) 
0 0 84 (99) 0 26 (6) 106 (13) NR 43 (51) 
REVERSE 
[45-48] 
CRT
-D 
610 62.9 (10.6) 
327 
(78) 
75 (18) 344 (82) 0 0 
26.8 
(7.0) 
153 (21) 470 (77) 236 (56) 
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Study Arm  N * 
Age- mean 
(SD) 
Male- 
n (%) 
NYHA I n (%) 
Mean 
LVEF 
(SD) 
QRS 
duration 
(ms)- Mean 
(SD)  
LBBB 
morphology 
-n (%) 
Ischaemic 
-n(%) I II III IV 
ICD 61.8 (11.6) 
152 
(80) 
32 (17) 159 (83) 0 0 
26.4 
(7.1) 
154 (24) 97 (51) 
Rhythm-ICD 
[49] 
CRT
-D 
178 
NR NR 1 (0.8) 6 (5.0) 
104 
(87.4) 
8 (6.7) 
25.6 
(8.3) 
169 (16) NR NR 
ICD NR NR 2 (3.4) 4 (6.8) 50 (84.7) 3 (5.1) 
23.3 
(6.4) 
167 (15) NR NR 
SCD-HeFT 
[50 51] 
ICD 
252
1 
60.1 (51.9-
69.2) † 
639 
(77) 
0 566 (68) 263 (32) 0 
24 ( 
19.0-
30.0) † 
NR NR 431 (52) 
Ami
odar
one 
60.4 (51.7-
68.3) † 
639 
(76) 
0 601 (71) 244 (29) 0 
25 (20.0-
30.0) † 
NR NR 426 (50) 
Plac 59.7 (51.2- 655 0 594 (70) 253 (30) 0 25 (20.0- NR NR 453 (53) 
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Study Arm  N * 
Age- mean 
(SD) 
Male- 
n (%) 
NYHA I n (%) 
Mean 
LVEF 
(SD) 
QRS 
duration 
(ms)- Mean 
(SD)  
LBBB 
morphology 
-n (%) 
Ischaemic 
-n(%) I II III IV 
ebo 67.8) † (77) 30.0) † 
Vector [52]
#
 
CRT
-P 106 67.1 (9.7) 
90 
(62.5) 
0 42 (29%) 94 (65%) 9 (6%) 
NR NR NR NR 
MT NR NR NR NR 
 
 
* randomised; †Median (inter quartile range); ‡Mean (range); § data reported for 67 patients at baseline rather than 58 randomised; ǁ group allocation prior to 
cross-over; 
#
baseline characteristics include 38 non-randomised patients in addition to the 106 randomised. 
SD=standard deviation; NYHA = New York Heart Association functional class; LVEF = left ventricular ejection fraction; LBBB = left bundle branch block.
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Table S2: Assessment of risk of bias of included studies 
Study reference 
Reporting of 
randomization 
Reporting of 
allocation 
concealment 
Reporting of blind 
treatment assignment/ 
blind outcome 
assessment 
Description of 
pts. baseline 
characteristics/ 
group balance 
Analysis 
based  on ITT 
AMIOVIRT Unclear Unclear Adequate Adequate Adequate 
CARE-HF Adequate Adequate Adequate Adequate Adequate 
CAT Unclear Adequate Unclear Adequate Unclear 
COMPANION Unclear Unclear Adequate Adequate Adequate 
Contak-CD Unclear Unclear Unclear Adequate Unclear 
DEFINITE  Unclear Unclear Adequate Adequate Adequate 
MADIT Unclear Unclear Unclear Adequate Adequate 
MADIT-CRT Unclear Adequate Adequate Adequate Adequate 
MADIT II Unclear Adequate Unclear Adequate Adequate 
MIRACLE Unclear Adequate Adequate Adequate Adequate 
MIRACLE-ICD Adequate Adequate Adequate Adequate Adequate 
MIRACLE-ICD 
II Adequate Adequate Adequate Adequate Adequate 
MUSTIC Unclear Unclear Inadequate Adequate Adequate 
Piccirillo et al Unclear Unclear Unclear Adequate Unclear 
Pinter et al  Unclear Unclear Adequate Adequate Unclear 
RAFT Unclear Adequate Adequate Adequate Adequate 
RESPOND  Adequate Adequate Unclear Adequate Adequate 
RETHINQ Adequate Adequate Adequate Adequate Adequate 
REVERSE Unclear Unclear Adequate Adequate Adequate 
17 
 
 
  
RHYTHM  ICD Unclear Unclear Unclear unclear Unclear 
SCD- HeFT Unclear Unclear Adequate Adequate Adequate 
Vector Unclear Unclear Unclear Unclear Unclear 
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Table S3. Multivariate adjusted model 
 
 
  
Variable Hazard ratio Lower 95% CI Upper 95% CI 
ICD* 0.77 0.52 1.13 
CRT-P* 0.74 0.42 1.28 
CRT-D* 0.55 0.35 0.86 
QRS<120 0.73 0.59 0.91 
QRS>=120 1.05 0.86 1.27 
LBBB 0.85 0.70 1.03 
AGE>=60 1.82 1.57 2.11 
GENDER=M 1.35 1.14 1.60 
ICD*QRS<120 1.08 0.78 1.49 
ICD*QRS>=120 0.90 0.70 1.17 
ICD*LBBB 1.07 0.82 1.39 
ICD*GENDER=M 0.75 0.59 0.97 
ICD*AGE>=60 1.23 0.98 1.55 
CRTP*QRS>=120 1.17 0.83 1.65 
CRTP*LBBB 0.88 0.62 1.25 
CRTP*GENDER=M 1.24 0.86 1.77 
CRTP*AGE>=60 0.86 0.62 1.21 
CRTD*QRS>=120 1.13 0.87 1.48 
CRTD*LBBB 0.88 0.67 1.16 
CRTD*GENDER=M 1.16 0.84 1.58 
CRTD*AGE>=60 0.98 0.74 1.28 
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* Reference category is a patient receiving OMT, <60 years of age, female, QRS duration ≥150ms and non-LBBB 
conduction abnormality. CI = confidence interval.  
ICD = implantable cardioverter defibrillator; CRT-P = cardiac resychronisation therapy pacemaker; CRT-D = cardiac 
resychronisation therapy defibrillator; LBBB = left bundle branch block. 
 
Table S4. Multivariate adjusted model – sensitivity analysis excluding patients with QRS<120 or 
NYHA Class I 
Variable Hazard ratio Lower 95% CI Upper 95% CI 
ICD* 0.78 0.50 1.21 
CRT-P* 0.66 0.37 1.18 
CRT-D* 0.49 0.30 0.79 
QRS>=120 1.08 0.89 1.31 
LBBB 0.84 0.69 1.03 
AGE>=60 1.59 1.31 1.94 
GENDER=M 1.39 1.12 1.73 
ICD*QRS>=120 0.90 0.69 1.18 
ICD*LBBB 1.04 0.79 1.37 
ICD*GENDER=M 0.76 0.56 1.03 
ICD*AGE>=60 1.19 0.89 1.58 
CRTP*QRS>=120 1.14 0.80 1.61 
CRTP*LBBB 0.92 0.64 1.31 
CRTP*GENDER=M 1.20 0.82 1.76 
CRTP*AGE>=60 0.97 0.68 1.39 
CRTD*QRS>=120 1.12 0.86 1.48 
CRTD*LBBB 0.89 0.67 1.18 
CRTD*GENDER=M 1.11 0.79 1.56 
CRTD*AGE>=60 1.14 0.84 1.55 
* Reference category is a patient receiving OMT, <60 years of age, female, QRS duration ≥150ms and non-LBBB 
conduction abnormality. CI = confidence interval.  
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ICD = implantable cardioverter defibrillator; CRT-P = cardiac resychronisation therapy pacemaker; CRT-D = cardiac 
resychronisation therapy defibrillator; LBBB = left bundle branch block. 
  
21 
 
Table S5. Subgroup-specific treatment effects predicted by multivariate adjusted network meta-analysis – sensitivity analysis excluding patients with 
QRS<120 or NYHA Class I 
Gender Age QRS LBBB CRT-D vs. MT CRT-P vs. MT ICD vs. MT CRT-D vs. CRT-P CRT-D vs. ICD ICD vs. CRT-P 
    Hazard ratio (95% confidence interval) 
Female 
<60 
<120 N       
≥120-<150 N 0.55(0.34 ,0.87) 0.76(0.43 ,1.33) 0.71(0.47 ,1.07) 0.72(0.40 ,1.31) 0.77(0.49 ,1.23) 0.93(0.53 ,1.65) 
≥120-<150 Y 0.48(0.31 ,0.76) 0.69(0.41 ,1.17) 0.74(0.49 ,1.12) 0.70(0.40 ,1.21) 0.66(0.42 ,1.03) 1.06(0.62 ,1.81) 
≥150 N 0.49(0.30 ,0.79) 0.66(0.37 ,1.18) 0.78(0.50 ,1.21) 0.73(0.40 ,1.34) 0.62(0.39 ,0.99) 1.18(0.66 ,2.10) 
≥150 Y 0.43(0.28 ,0.66) 0.61(0.38 ,0.97) 0.81(0.55 ,1.20) 0.71(0.42 ,1.18) 0.53(0.35 ,0.80) 1.34(0.82 ,2.18) 
≥60 
<120 N       
≥120-<150 N 0.62(0.41 ,0.95) 0.73(0.44 ,1.22) 0.84(0.58 ,1.21) 0.85(0.50 ,1.44) 0.74(0.50 ,1.11) 1.14(0.69 ,1.9) 
≥120-<150 Y 0.55(0.37 ,0.82) 0.67(0.43 ,1.06) 0.88(0.61 ,1.26) 0.82(0.51 ,1.33) 0.63(0.43 ,0.92) 1.30(0.81 ,2.07) 
≥150 N 0.56(0.36 ,0.86) 0.65(0.39 ,1.06) 0.93(0.63 ,1.38) 0.86(0.51 ,1.45) 0.60(0.40 ,0.90) 1.44(0.87 ,2.38) 
≥150 Y 0.49(0.35 ,0.70) 0.59(0.41 ,0.85) 0.97(0.70 ,1.34) 0.83(0.55 ,1.25) 0.51(0.36 ,0.71) 1.64(1.10 ,2.43) 
          
Male <60 <120 N       
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≥120-<150 N 0.61(0.42 ,0.87) 0.91(0.58 ,1.41) 0.53(0.39 ,0.73) 0.67(0.42 ,1.06) 1.13(0.80 ,1.61) 0.59(0.38 ,0.92) 
≥120-<150 Y 0.54(0.36 ,0.79) 0.83(0.54 ,1.28) 0.56(0.39 ,0.80) 0.65(0.41 ,1.03) 0.96(0.67 ,1.39) 0.67(0.43 ,1.06) 
≥150 N 0.54(0.37 ,0.79) 0.80(0.50 ,1.26) 0.59(0.42 ,0.84) 0.68(0.42 ,1.09) 0.91(0.64 ,1.30) 0.74(0.46 ,1.19) 
≥150 Y 0.48(0.34 ,0.67) 0.73(0.50 ,1.06) 0.62(0.44 ,0.85) 0.65(0.43 ,0.99) 0.77(0.56 ,1.07) 0.84(0.56 ,1.27) 
≥60 
<120 N       
≥120-<150 N 0.69(0.52 ,0.92) 0.88(0.61 ,1.27) 0.64(0.50 ,0.81) 0.79(0.54 ,1.15) 1.09(0.85 ,1.40) 0.72(0.50 ,1.05) 
≥120-<150 Y 0.61(0.45 ,0.83) 0.81(0.56 ,1.16) 0.66(0.49 ,0.89) 0.76(0.52 ,1.11) 0.93(0.71 ,1.21) 0.82(0.56 ,1.20) 
≥150 N 0.62(0.46 ,0.83) 0.77(0.54 ,1.11) 0.70(0.53 ,0.94) 0.80(0.55 ,1.15) 0.88(0.67 ,1.14) 0.91(0.63 ,1.32) 
≥150 Y 0.55(0.43 ,0.70) 0.71(0.56 ,0.90) 0.73(0.57 ,0.94) 0.77(0.58 ,1.02) 0.74(0.61 ,0.91) 1.03(0.77 ,1.38) 
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Figure S1: Hazard ratios on all-cause mortality for individual studies included in individual patient 
data 
  
Hazard ratio 95% CI
0.40 0.63 1.00 1.58 2.51
CRT-D OMT Companion 0.64(0.48,0.86)
CRT-P OMT CARE-HF 0.64(0.48,0.85)
CRT-P OMT Companion 0.76(0.58,1.01)
CRT-P OMT MIRACLE 0.92(0.56,1.53)
CRT-P OMT REVERSE CRT-P 1(0.32,3.16)
CRT-D CRT-P Companion 0.84(0.65,1.09)
ICD OMT DEFINITE 0.62(0.38,1)
ICD OMT MADIT 0.35(0.19,0.63)
ICD OMT MADIT II 0.69(0.52,0.9)
ICD OMT SCD-HeFT 0.75(0.63,0.89)
CRT-D ICD CONTAK_CD 0.83(0.59,1.16)
CRT-D ICD MADIT-CRT 0.92(0.65,1.31)
CRT-D ICD MIRACLEICD 0.93(0.62,1.4)
CRT-D ICD RAFT 0.75(0.62,0.91)
CRT-D ICD RethinQ 1.94(0.65,5.79)
CRT-D ICD REVERSE CRT-D 0.67(0.38,1.17)
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Further information on searches 
Search syntax 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 
<1948 to Present> 
Search run on 27/06/2011 
1     (CRT or "cardiac resynchron$ therap$").tw. (6517) 
2     resynchron$ therap$.tw. (2829) 
3     BVP.tw. (170) 
4     Cardiac Resynchronization Therapy/ (228) 
5     (biventricular adj10 pac$).tw. (1261) 
6     (biventricular adj10 stimulat$).tw. (157) 
7     ((cardiac or heart) adj10 resynch$).tw. (3034) 
8     (coronary adj10 resynch$).tw. (131) 
9     (atriobiventricular adj10 pac$).tw. (14) 
10     (atrio biventricular adj10 pac$).tw. (23) 
11     CRT-P.tw. (133) 
12     CRT-D.tw. (176) 
13     cardioversion.tw. (4098) 
14     cardioverter.tw. (6545) 
15     Defibrillators, Implantable/ (8786) 
16     (internal adj3 (defibrillat$ or cardioverter)).tw. (422) 
17     (implant adj3 (cardioverter or defibrillat$)).tw. (122) 
18     (cardiac adj3 defibrillat$).tw. (1061) 
19     ((implant or internal or cardiac) and defib$).tw. (7618) 
20     icd.tw. (14797) 
21     or/1-20 (35301) 
22     Intraventricular conduction delay$.tw. (271) 
23     Dilated cardiomyopathy.tw. (10812) 
25 
 
24     (Sudden death adj3 cardiac).tw. (801) 
25     ((prolonged or wide) adj2 QRS).tw. (1056) 
26     (Premature ventricular adj1 (complex$ or contraction)).tw. (794) 
27     ((Reduced or low) adj ejection fraction).tw. (1045) 
28     ((impaired or dysfunction or function) adj3 (left ventric$ or LVEF or LV)).tw. (37111) 
29     (ventricular adj1 (tachycardia or fibrillation)).tw. (25008) 
30     arrhythmi$.tw. (57496) 
31     heart failure.tw. (85570) 
32     ((cardiac or ventricular or intraventricular) adj5 asynchron$).tw. (444) 
33     ((cardiac or ventricular or intraventricular) adj5 dyssynchron$).tw. (882) 
34     cardiac arrest.tw. (16215) 
35     tachycardia, ventricular/ (8877) 
36     Arrhythmias, Cardiac/ (47995) 
37     Heart Failure/ (71586) 
38     Death, Sudden, Cardiac/ (9017) 
39     Ventricular Dysfunction, Left/ or Bundle-Branch Block/ (23476) 
40     Bundle Branch Block.tw. (6055) 
41     Ventricular Fibrillation/ (13640) 
42     Heart Arrest/ (19743) 
43     Myocardial Infarction/ (126739) 
44     or/22-43 (368895) 
45     Randomized controlled trials as Topic/ (73673) 
46     Randomized controlled trial/ (309567) 
47     Random allocation/ (71762) 
48     Double blind method/ (110773) 
49     Single blind method/ (15106) 
50     Clinical trial/ (463846) 
51     exp Clinical Trials as Topic/ (242485) 
26 
 
52     clinical trial/ or clinical trial, phase i/ or clinical trial, phase ii/ or clinical trial, phase iii/ or 
clinical trial, phase iv/ or multicenter study/ (558228) 
53     or/45-52 (851498) 
54     randomized controlled trial.pt. (309567) 
55     controlled clinical trial.pt. (82654) 
56     random allocation.sh. (71762) 
57     double blind method.sh. (110773) 
58     single blind method.sh. (15106) 
59     (clin$ adj25 trial$).tw. (200910) 
60     ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$ or dummy$)).tw. (114910) 
61     Placebos/ (29766) 
62     Placebo$.tw. (133939) 
63     Random$.tw. (553900) 
64     or/54-63 (914706) 
65     53 or 64 (1220129) 
66     Case report.tw. (168393) 
67     Letter/ (733158) 
68     Historical article/ (275454) 
69     or/66-68 (1167008) 
70     65 not 69 (1192243) 
71     21 and 44 and 70 (3760) 
72     animals/ not (animals/ and humans/) (3520949) 
73     71 not 72 (3508) 
74     limit 73 to english language (3198) 
75     limit 74 to yr="1990 -Current" (3152) 
Database: Embase<1988 to 2011 Week 25> 
Search run on 27/06/2011 
1     (CRT or "cardiac resynchron$ therap$").tw. (9071) 
27 
 
2     resynchron$ therap$.tw. (4112) 
3     BVP.tw. (178) 
4     cardiac resynchronization therapy/ (5525) 
5     (biventricular adj10 pac$).tw. (1670) 
6     (biventricular adj10 stimulat$).tw. (219) 
7     ((cardiac or heart) adj10 resynch$).tw. (4377) 
8     (coronary adj10 resynch$).tw. (167) 
9     (atrio biventricular adj10 pac$).tw. (30) 
10     (atriobiventricular adj10 pac$).tw. (20) 
11     CRT-P.tw. (242) 
12     CRT-D.tw. (485) 
13     cardioversion.tw. (4285) 
14     cardioverter.tw. (7839) 
15     (internal adj3 (defibrillat$ or cardioverter)).tw. (442) 
16     (implant$ adj3 (cardioverter or defibrillat$)).tw. (9516) 
17     (cardiac adj3 defibrillat$).tw. (1115) 
18     ((implant or internal or cardiac) and defib$).tw. (8844) 
19     icd.tw. (20125) 
20     *defibrillator/ (6658) 
21     or/1-20 (44411) 
22     *Heart arrest/ (10051) 
23     *myocardial infarction/ (48787) 
24     *Death,-Sudden,-Cardiac/ (8275) 
25     cardiac arrest.tw. (15652) 
26     Intraventricular conduction delay$.tw. (280) 
27     Dilated cardiomyopathy.tw. (12299) 
28     (sudden death adj3 cardiac).tw. (818) 
29     ((prolonged or wide) adj2 QRS).tw. (1190) 
28 
 
30     (Premature ventricular adj1 (complex$ or contraction)).tw. (699) 
31     ((Reduced or low) adj ejection fraction).tw. (1302) 
32     ((impaired or dysfunction or function) adj3 (left ventric$ or LVEF or LV)).tw. (39565) 
33     (ventricular adj1 (tachycardia or fibrillation)).tw. (22091) 
34     arrhythmi$.tw. (52667) 
35     *congestive cardiomyopathy/ (5894) 
36     *heart muscle conduction system/ (1786) 
37     *heart arrhythmia/ (18228) 
38     *heart bundle branch block/ (712) 
39     *heart failure/ (39054) 
40     *congestive heart failure/ (17950) 
41     heart failure.tw. (96051) 
42     ((cardiac or ventricular or intraventricular) adj5 asynchron$).tw. (464) 
43     ((cardiac or ventricular or intraventricular) adj5 dyssynchron$).tw. (1299) 
44     *Bundle-Branch Block/ (712) 
45     Bundle Branch Block.tw. (4682) 
46     *heartventricletachycardia/ (8113) 
47     *syncope/ (5496) 
48     *heartventricle fibrillation/ (5098) 
49     or/22-48 (273295) 
50     Clinical trial/ (758285) 
51     Randomized controlled trial/ (265459) 
52     Randomization/ (49808) 
53     Single blind procedure/ (13620) 
54     Double blind procedure/ (90508) 
55     Crossover procedure/ (29846) 
56     Placebo/ (146356) 
57     Rct.tw. (6934) 
29 
 
58     random*.tw. (588686) 
59     (clinical trial$ or controlled clinical trial$ or major clinical stud$ or controlled stud$).tw. 
(219539) 
60     (clinical adj25 trial$).tw. (213401) 
61     ((single$ or double$ or treble$ or triple$) and (blind$ or mask$)).tw. (117874) 
62     Placebo$.tw. (137596) 
63     Prospective study/ (157946) 
64     or/50-63 (1381558) 
65     Case study/ (10159) 
66     Abstract report/ or letter/ (611863) 
67     or/65-66 (621895) 
68     64 not 67 (1352204) 
69     21 and 49 and 68 (4664) 
70     limit 69 to english language (4204) 
71     animal/ not (animal/ and human/) (526120) 
72     animal experiment/ (1040422) 
73     71 or 72 (1559640) 
74     70 not 73 (3995) 
75     conference.so. (435795) 
76     74 not 75 (3512) 
77     limit 76 to yr="1990 -Current" (3499) 
Database: Cochrane  
Search run on: 28/06/2011  
#1 (CRT or cardiac resynchron* therap*):ti,ab,kw in Clinical Trials  647 
#2 (resynchron* therap*):ti,ab,kw in Clinical Trials  204 
#3 (BVP):ti,ab,kw in Clinical Trials 14 
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#4 MeSH descriptor Cardiac Resynchronization Therapy, this term only 4 
#5 (biventricular NEAR pac*):ti,ab,kw in Clinical Trials  108 
#6 (biventricular NEAR stimulat*):ti,ab,kw in Clinical Trials  16 
#7 ((cardiac or heart) NEAR resynch*):ti,ab,kw in Clinical Trials  205 
#8 (coronary NEAR resynch*):ti,ab,kw in Clinical Trials  3 
#9 (atriobiventricular NEAR pac*):ti,ab,kw in Clinical Trials  3 
#10 (atrio biventricular NEAR pac*):ti,ab,kw in Clinical Trials  11 
#11 (CRT-P):ti,ab,kw in Clinical Trials 23 
#12 (CRT -D):ti,ab,kw in Clinical Trials 58 
#13 (cardioversion):ti,ab,kw in Clinical Trials 546 
#14 (cardioverter):ti,ab,kw in Clinical Trials  470 
#15 MeSH descriptor Defibrillators, Implantable, this term only 734 
#16 (internal NEAR (defibrillat* or cardioverterter)):ti,ab,kw in Clinical Trials  19 
#17 (implant NEAR (cardioverter OR defibrillat*)):ti,ab,kw in Clinical Trials 119 
#18 (cardiac NEAR defibrillat*):ti,ab,kw in Clinical Trials  283 
#19 ((implant OR internal OR cardiac) AND defib*):ti,ab,kw in Clinical Trials  709 
#20 (icd):ti,ab,kw in Clinical Trials 780 
#21 
(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 
OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20) 
2746 
#22 (intraventricular conduction delay):ti,ab,kw in Clinical Trials  31 
#23 (Dilated cardiomyopathy):ti,ab,kw in Clinical Trials  551 
#24 (Sudden death NEAR cardiac):ti,ab,kw in Clinical Trials 641 
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#25 ((prolonged or wide) NEAR QRS):ti,ab,kw in Clinical Trials  84 
#26 
(Premature ventricular NEAR (complex* or contraction)):ti,ab,kw in Clinical 
Trials 
415 
#27 ((Reduced or low) NEAR ejection fraction):ti,ab,kw in Clinical Trials  446 
#28 
((impaired or dysfunction or function) NEAR ( left ventric* or LVEF or 
LV)):ti,ab,kw in Clinical Trials 
4865 
#29 (ventricular NEAR (tachycardia or fibrillation)):ti,ab,kw in Clinical Trials 1673 
#30 (heart failure):ti,ab,kw in Clinical Trials  8459 
#31 
((cardiac or ventricular or intraventricular) NEAR asynchron*):ti,ab,kw in 
Clinical Trials 
25 
#32 
((cardiac or ventricular or intraventricular) NEAR dyssynchron*):ti,ab,kw in 
Clinical Trials 
56 
#33 MeSH descriptor Arrhythmias, Cardiac, this term only 1604 
#34 MeSH descriptor Heart Failure, this term only 4620 
#35 MeSH descriptor Ventricular Dysfunction, Left, this term only  1412 
#36 (Bundle Branch Block):ti,ab,kw in Clinical Trials 178 
#37 (arrhythmi*):ti,ab,kw in Clinical Trials 5106 
#38 (cardiac arrest):ti,ab,kw in Clinical Trials  990 
#39 MeSH descriptor Heart Arrest, this term only 533 
#40 MeSH descriptor Death, Sudden, Cardiac explode all trees 452 
#41 MeSH descriptor Bundle-Branch Block explode all trees 79 
#42 MeSH descriptor Ventricular Fibrillation explode all trees 425 
32 
 
#43 MeSH descriptor Myocardial Infarction explode all trees 7646 
#44 
(#22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR 
#31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR 
#40 OR #41 OR #42 OR #43) 
23964 
#45 (#21 AND #44), from 1990 to 2011 1418 
#46 (#45) 1207 
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